TABLE 1.
Demographic and clinicopathologic characteristics of all patients
| Variable | All patients (n = 30) |
|---|---|
|
| |
| Age (years), median (SD) | 60.5 (9.6) |
| Gender, n (%) | |
| Female | 12 (40) |
| Male | 18 (60) |
| Race, n (%) | |
| White | 20 (67) |
| Black/African American | 3 (10) |
| Asian | 3 (10) |
| Unknown | 4 (13) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 3 (10) |
| Non-Hispanic | 27 (90) |
| Baseline CA19-9 (U/ml), median (IQR) | 14.8 (3.8–258.8) |
| Follow-up (months), median (IQR) | 17 (9–30) |
| NGS completed, n (%) | 19 (63) |
| Positive actionable mutation, n (%)a | 6 (32) |
| Best response to treatment, n (%)b | |
| Partial response | 7 (23) |
| Stable disease | 20 (67) |
| Progression disease | 3 (10) |
NGS next generation sequencing, SD standard deviation, IQR interquartile range, CA19-9 carbohydrate antigen 19–9
a
Positive mutation for most common actionable targets, FGFR-2 fusion, IDH-1
b
According to RECIST, version 1.1